MK-2206

MK-2206
Names
IUPAC name
8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
Identifiers
3D model (Jmol) Interactive image
ChemSpider 24658140
PubChem 24964624
Properties
C25H21N5O
Molar mass 407.48 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O.[1] It acts as an allosteric AKT inhibitor.[2]

It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.[1]

It is intended to be used with other cancer therapies that advanced tumours may become resistant to.[3]

Clinical trials

2011: A phase 1 clinical trial of MK-2206 alone has reported it was well tolerated.[4]
2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects.[3]
2016: MK-2206 is one of the treatments in the I-SPY2 Adaptive clinical trial for breast cancer that had been selected for later stage trials.[5]

References

This article is issued from Wikipedia - version of the 7/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.